news
Researchers make cancer immunotherapy ‘breakthrough’
4 March 2016 | By Victoria White
Researchers have found the tools necessary to give immunotherapy the precision guidance that patients with cancer so desperately need...
List view / Grid view
Immunotherapy
article
Directing a weaponised attack on cancer with Natural Killer Receptor T-Cells
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
whitepaper
Application Note: Multiparameter profiling of a Structure Activity Relationship (SAR) library for immunological activity in human PBMCs
We describe a no-wash, high throughput screen that provides a multiparametric activity profile for a structure activity relationship (SAR) library derived from immunomodulatory compounds...
news
Accelerate development of Cancer Immunotherapy (iOnc) drugs with new PathHunter® Checkpoint Assays from DiscoveRx
14 January 2016 | By DiscoveRx
DiscoveRx Corporation announced the expansion of its PathHunter cell-based assays portfolio with the release of PathHunter Checkpoint Assays...
news
Early immune effect of SCIB1 observed by ImmunTraCkeR diagnostic
11 January 2016 | By Victoria White
Cancer vaccine SCIB1 is a DNA ImmunoBody immunotherapy encoding a human IgG1 antibody, with three epitopes from gp100 and one from TRP-2 engineered into its CDR regions...
news
Novartis expands its cancer immunotherapy portfolio
21 October 2015 | By Victoria White
Novartis is broadening its portfolio of cancer immunotherapies through the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corporation...
whitepaper
Whitepaper: Multiplexed cancer immune response analysis nCounter® PanCancer Immune Profiling Panel for gene expression
The ability of mutated cells to give rise to pathological cancer relies upon the capability of these cells to evade immune recognition, suppress immune activity, and persist in a chronically inflamed environment. Tremendous growth in the understanding of these complex processes is beginning to generate breakthroughs in the treatment of…
news
First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria
1 September 2015 | By Nick Jackson
As a precursor to the Phase III trial, this Phase IIb study will select the optimum dose, and is being conducted in Germany under the Therapy Allergens Ordinance (Therapieallergene-Verordnung)...
news
Medimmune and Inovio Pharmaceuticals agree to DNA-based immunotherapy collaboration
11 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.
news
Bristol-Myers Squibb will win big with melanoma combination immunotherapy
23 June 2015 | By Victoria White
Data presented at ASCO 2015 suggests that the Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape...
news
Amgen and Roche collaborate on cancer immunotherapy study with talimogene laherparepvec and atezolizumab
2 June 2015 | By Victoria White
Amgen and Roche are to collaborate on a study to evaluate talimogene laherparepvec in combination with atezolizumab in patients with cancer...
news
World first as viral immunotherapy T-VEC shows patient benefit in Phase III trial
26 May 2015 | By Victoria White
A genetically engineered herpes virus, T-VEC, can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action...
news
Investigational immunotherapy MPDL3280A doubled the likelihood of survival compared with chemotherapy in people with NSCLC
14 May 2015 | By Victoria White
Roche has announced interim results from a global, randomised Phase II study (POPLAR) of MPDL3280A in people with previously treated NSCLC...
news
Inovio initiates Phase I trial of its Ebola DNA immunotherapy
12 May 2015 | By Victoria White
Inovio Pharmaceuticals has initiated a Phase I trial to evaluate safety, tolerability and immune responses of its Ebola DNA immunotherapy...
news
First patient dosed in Phase 1 trial of CM-24, a novel immune checkpoint inhibitor for cancer immunotherapy
20 April 2015 | By Victoria White
The first patient has been dosed in a Phase 1 clinical trial of CM-24, a first-in-class immunomodulatory mAb for the treatment of various types of cancers...
